Antithrombin Alfa
drugOn this page
Also known as Antithrombin (recombinant)Antithrombin iiirecombinantAntithrombine alfaAntitrombina alfaAtrynKW-3357
Summary
Antithrombin Alfa (CHEMBL1201554) is an approved protein; indicated across 4 conditions including hereditary antithrombin deficiency and preeclampsia.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Protein
- Indications: 4 conditions
- Clinical trials: 6
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201554 |
| Name | Antithrombin Alfa |
| Type | Protein |
| Max phase | 4 |
Also known as: Antithrombin (recombinant), Antithrombin alfa, Antithrombin iii, recombinant, Antithrombine alfa, Antitrombina alfa, Atryn, KW-3357, ANTITHROMBIN ALFA
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
4 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| hereditary antithrombin deficiency | 4 | MONDO:0013144 | HP:0001976 |
| preeclampsia | 3 | MONDO:0005081 | EFO:0000668 |
| disseminated intravascular coagulation | 3 | MONDO:0001243 | HP:0005521 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 6.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 3 |
| PHASE1 | 3 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01384396 | PHASE3 | COMPLETED | A Clinical Study of KW-3357 in Patients With DIC |
| NCT01384409 | PHASE3 | TERMINATED | A Phase 3 Clinical Study of KW-3357 in Patients With DIC |
| NCT01384903 | PHASE3 | COMPLETED | An Open-label Study of KW-3357 |
| NCT00938288 | PHASE1 | COMPLETED | A Study of KW-3357 in Congenital Antithrombin Deficiency |
| NCT01158729 | PHASE1 | TERMINATED | Antithrombin III Supplementation for Cardiopulmonary Bypass in Neonates |
| NCT01598883 | PHASE1 | COMPLETED | Understanding Heparin Resistance in Cardiac Surgery |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).